What this trial means for you
This study is active, not recruiting — it is not currently taking new participants, but its results may matter for treatments you're considering. It's studying Orforglipron, Placebo for hypertension.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of hypertension in participants with obesity or overweight.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria: * Has systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg (if DBP criteria alone is met, SBP must be ≥130 mmHg) at screening (Visit 1). * Has SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg (if DBP criteria alone is met, SBP must be ≥130 mmHg) at week 0 (Visit 3). * Untreated for hypertension, or on stable antihypertensive medications ≥ 30 days prior to Visit 1. * Have a body mass index (BMI) ≥ 25 kg/m². Exclusion Criteria: * Has SBP ≥170 mmHg and/or DBP ≥110 mmHg at Visit 1 or at Visit 3. * Has known secondary causes of hypertension * Have heart failure with reduced ejection fraction (HFrEF) diagnosis * Have had any of the following conditions within 90 days prior to screening. * hospitalization for hypertension or for congestive heart failure * acute coronary syndrome or acute myocardial infarction, or * cerebrovascular accident (stroke). * Have type 1 diabetes (T1D) * Have acute or chronic hepatitis, including a history of autoimmune hepatitis
Study sites by state
Arizona
- Elite Clinical Studies, LLC — Phoenix
California
- Valley Clinical Trials, Inc. — Covina
- Valley Clinical Trials, Inc. — Northridge
Connecticut
- Chase Medical Research, LLC — Waterbury
Florida
- Excel Medical Clinical Trials — Boca Raton
- Care Access - Brandon — Brandon
- Northeast Research Institute - Downtown Office — Jacksonville
- Care Access - St. Petersburg — St. Petersburg
Hawaii
- East-West Medical Research Institute — Honolulu
Maryland
- Sinai Hospital Of Baltimore — Baltimore
- Ascension Saint Agnes Heart Care — Baltimore
Massachusetts
- Lucida Clinical Trials — New Bedford
Michigan
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division — Troy
Missouri
- StudyMetrix Research — City of Saint Peters
Nevada
- Excel Clinical Research, LLC — Las Vegas
- Palm Research Center Sunset — Las Vegas
New York
- Rochester Clinical Research, LLC — Rochester
Ohio
- Remington-Davis, Inc — Columbus
- PriMED Clinical Research — Dayton
Oregon
- Advanced Research Institute - Tigard — Tigard
South Carolina
- Care Access - Mauldin — Mauldin
Texas
- Dallas Heart and Vascular Consultants, PA — Duncanville
- Texas Institute of Cardiology, PA — McKinney
- North Hills Family Medicine/North Hills Medical Research — North Richland Hills
Utah
- Advanced Research Institute — Ogden
Virginia
- Carient Heart & Vascular - Manassas — Manassas
- Health Research of Hampton Roads, Inc. — Newport News
- National Clinical Research, Inc — Richmond
Washington
- Eastside Research Associates — Redmond
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.
Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in
.env to activate this form.)